Preoperative dual antiplatelet therapy increases risk after urgent coronary bypass surgery: A Netherlands heart registration study.

OBJECTIVE

Dual antiplatelet therapy (DAPT) is standard care after acute coronary syndrome, but its perioperative management before urgent coronary artery bypass grafting (CABG) remains controversial. By using data from the Netherlands Heart Registration, a nationwide Dutch registry, we sought to assess the impact of recent preoperative DAPT on surgical and postoperative outcomes in patients undergoing urgent CABG after acute coronary syndrome.

METHODS

In this multicenter retrospective cohort study, 6913 patients undergoing urgent isolated CABG within 90 days of acute coronary syndrome were analyzed. Patients receiving DAPT (aspirin + P2Y12 inhibitor within 48 hours preoperatively) were compared with those on aspirin alone. Propensity score matching and multivariable logistic regression were used to adjust for confounding.

RESULTS

Recent DAPT use was independently associated with increased perioperative bleeding complications, including greater rates of reintervention (odds ratio [OR], 1.78), transfusion (OR, 1.85), and surgical mortality (OR, 2.02). Considerable interhospital variation in DAPT use (12%-84%) underscores inconsistent practices across Dutch cardiac surgery centers.

CONCLUSIONS

Recent DAPT before urgent CABG is independently associated with significantly increased perioperative bleeding risk, transfusion requirements, and mortality. The substantial interhospital variation in DAPT use across Dutch cardiac surgery centers further underscores the need for standardized, evidence-based guidelines to optimize antiplatelet management in high-risk patients with coronary syndrome requiring surgical revascularization.